Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Cancer Therapies02:49

Cancer Therapies

10.6K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
10.6K
Cancer Therapies02:49

Cancer Therapies

2.9K
2.9K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

9.1K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
9.1K
Stem Cell Therapy for Tissue Regeneration01:21

Stem Cell Therapy for Tissue Regeneration

4.8K
Stem cell therapy is a method used in regenerative medicine to repair and restore function to damaged tissues and organs. Stem cells have the potential to proliferate and differentiate into various tissue types, making them ideal candidates for tissue regeneration. For example, hematopoietic stem cell transplants are commonly used in blood cancer treatment to replenish damaged bone marrow and restore healthy blood cells.
Types of Stem Cells used in Stem Cell Therapy
The two main cell...
4.8K
Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

6.3K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
6.3K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

3.9K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.9K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Spatially-Resolved Multiomic Atlas of Leiomyosarcoma Identifies Two Clinically Relevant Epigenetically-Driven Cell States.

bioRxiv : the preprint server for biology·2026
Same author

Reply to: In DeFi-ance of "More Is Better": Questioning Long-Term Nirogacestat Use in Desmoid Tumors.

Journal of clinical oncology : official journal of the American Society of Clinical Oncology·2026
Same author

Tazemetostat, an EZH2 inhibitor, in solid tumors harboring SWI/SNF alterations: a phase II basket study.

Nature communications·2026
Same author

Deceptive Thyroid Pathologies: Anaplastic Thyroid Carcinoma Mimics and Clinical Implications.

Head & neck·2026
Same author

First-Line Chemotherapy Regimens for Advanced and Metastatic Leiomyosarcoma: Doxorubicin vs. Gemcitabine-A Systematic Review.

Cancers·2026
Same author

Outcomes Following Combined Modality Treatment to the Primary Site in Select Patients With Metastatic Soft Tissue Sarcoma.

Practical radiation oncology·2026
Same journal

Real-world safety, prognostic, and design considerations in ketogenic diet trials for pancreatic cancer.

Cancer·2026
Same journal

Proliferative ecotype determines lethal prognosis and therapeutic benefit in urothelial carcinoma.

Cancer·2026
Same journal

Reply to "Real-world safety, prognostic, and design considerations in ketogenic diet trials for pancreatic cancer".

Cancer·2026
Same journal

Pediatric cancer survival in the United States from 2001 to 2021.

Cancer·2026
Same journal

Updates on intratumoral therapies in melanoma.

Cancer·2026
Same journal

Correction to "Scientific highlights and perspectives from the International Inflammatory Breast Cancer Symposium 2025".

Cancer·2026
See all related articles

Related Experiment Video

Updated: Mar 17, 2026

Establishment of a Primary Culture of Patient-derived Soft Tissue Sarcoma
07:55

Establishment of a Primary Culture of Patient-derived Soft Tissue Sarcoma

Published on: April 11, 2018

15.3K

Chemotherapy for soft tissue sarcoma.

Ravin Ratan1, Shreyaskumar R Patel2

  • 1Department of Sarcoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas.

Cancer
|July 20, 2016
PubMed
Summary
This summary is machine-generated.

Doxorubicin and ifosfamide are key chemotherapy drugs for soft tissue sarcoma. Newer targeted therapies offer subtype-specific options, improving treatment for rare sarcomas.

Keywords:
adjuvantchemotherapydoxorubicindrug therapyifosfamidesarcoma

More Related Videos

A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing Neoadjuvant Therapies
07:15

A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing Neoadjuvant Therapies

Published on: July 28, 2020

10.4K
Cytotoxic Efficacy of Photodynamic Therapy in Osteosarcoma Cells In Vitro
08:04

Cytotoxic Efficacy of Photodynamic Therapy in Osteosarcoma Cells In Vitro

Published on: March 18, 2014

13.4K

Related Experiment Videos

Last Updated: Mar 17, 2026

Establishment of a Primary Culture of Patient-derived Soft Tissue Sarcoma
07:55

Establishment of a Primary Culture of Patient-derived Soft Tissue Sarcoma

Published on: April 11, 2018

15.3K
A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing Neoadjuvant Therapies
07:15

A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing Neoadjuvant Therapies

Published on: July 28, 2020

10.4K
Cytotoxic Efficacy of Photodynamic Therapy in Osteosarcoma Cells In Vitro
08:04

Cytotoxic Efficacy of Photodynamic Therapy in Osteosarcoma Cells In Vitro

Published on: March 18, 2014

13.4K

Area of Science:

  • Oncology
  • Medical Oncology
  • Sarcoma Research

Background:

  • Soft tissue sarcoma encompasses diverse rare tumors.
  • Doxorubicin and ifosfamide are established effective chemotherapies.
  • Treatment landscape evolves with new drug approvals and targeted therapies.

Purpose of the Study:

  • To review current treatment strategies for soft tissue sarcoma.
  • To highlight the role of established and novel therapeutic agents.
  • To discuss the impact of recent drug approvals on sarcoma management.

Main Methods:

  • Review of existing literature on soft tissue sarcoma treatments.
  • Analysis of chemotherapy efficacy, including dose-response relationships.
  • Examination of recent approvals for targeted therapies in specific sarcoma subtypes.

Main Results:

  • Doxorubicin and ifosfamide remain primary chemotherapy agents.
  • Fixed-dose-rate gemcitabine with or without docetaxel is a standard second-line option.
  • Newer agents like eribulin, trabectedin, pazopanib, and imatinib show subtype-specific efficacy.

Conclusions:

  • Optimal dosing and administration are crucial for chemotherapy effectiveness.
  • The use of single agents versus combination therapy is debated.
  • Subset-specific targeted therapies represent important advancements in soft tissue sarcoma treatment.